Last updated: September 15, 2026
FEXMID is a 7.5 mg immediate-release tablet containing cyclobenzaprine hydrochloride. Its commercial opportunity is driven less by composition-of-matter exclusivity and more by differentiated oral dosage forms, tolerability, patient convenience, and channel strategy. The core tablet has limited formulation complexity, leaving room for lactose-free, orally disintegrating, pediatric-friendly, geriatric-friendly, and potentially abuse-deterrent presentations.
What is FEXMID and how is it regulated?
FEXMID contains cyclobenzaprine hydrochloride, a centrally acting skeletal-muscle relaxant indicated for short-term treatment of acute, painful musculoskeletal conditions as an adjunct to rest and physical therapy. The FDA-approved product is an immediate-release 7.5 mg tablet.[1]
Cyclobenzaprine products are prescription drugs. FEXMID is subject to the FDA labeling limitations applicable to cyclobenzaprine, including short-term use, generally up to two or three weeks. The drug is structurally related to tricyclic antidepressants and has anticholinergic and sedating effects.[1]
| Attribute |
FEXMID profile |
| Active ingredient |
Cyclobenzaprine hydrochloride |
| Strength |
7.5 mg |
| Dosage form |
Immediate-release tablet |
| Route |
Oral |
| Therapeutic category |
Skeletal-muscle relaxant |
| Primary use |
Acute painful musculoskeletal conditions |
| Regulatory pathway |
FDA-approved prescription drug |
| Reference product class |
Cyclobenzaprine immediate-release tablets |
| Main commercial constraints |
Sedation, anticholinergic effects, short treatment duration |
FEXMID competes with generic cyclobenzaprine 5 mg and 10 mg tablets, extended-release cyclobenzaprine capsules, and other muscle relaxants such as tizanidine, methocarbamol, baclofen, and carisoprodol.
What excipients are used in FEXMID tablets?
FEXMID uses a conventional immediate-release tablet platform. Public product labeling identifies standard pharmaceutical excipients associated with tablet formation, disintegration, lubrication, flow, and film coating.[1]
The formulation strategy can be understood by function:
| Excipient function |
Typical formulation role in FEXMID-type tablets |
Commercial purpose |
| Diluent |
Lactose, microcrystalline cellulose, or an equivalent filler |
Provides tablet mass for a low-dose API |
| Binder |
Povidone or comparable polymer |
Improves granule and tablet strength |
| Disintegrant |
Croscarmellose sodium or sodium starch glycolate |
Promotes rapid tablet breakup |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow and content uniformity |
| Lubricant |
Magnesium stearate |
Reduces tooling friction and ejection force |
| Surfactant or wetting aid |
Sodium lauryl sulfate or comparable agent, where used |
Supports wetting and dissolution |
| Film coating |
Hypromellose, titanium dioxide, talc, polyethylene glycol, or related coating materials |
Improves appearance, handling, swallowability, and product identification |
The active dose is small relative to tablet mass. That creates a content-uniformity challenge because cyclobenzaprine hydrochloride represents only a limited percentage of the finished tablet. The excipient system must deliver consistent API distribution without slowing dissolution.
For an immediate-release product, the main formulation performance targets are:
- Rapid and reproducible disintegration.
- Uniform low-dose API distribution.
- Adequate hardness without excessive friability.
- Low sensitivity to lubricant overmixing.
- Acceptable dissolution across physiological pH conditions.
- Stable color and tablet identification during storage.
What excipient strategy is most appropriate for FEXMID?
The most defensible strategy is a direct-compression or dry-granulation platform using a spray-dried or co-processed filler-disintegrant system. Wet granulation is possible, but it adds processing steps and may offer limited benefit for a relatively low-dose, immediate-release tablet.
Low-dose content uniformity
Cyclobenzaprine hydrochloride is present at a low dose. A co-processed excipient containing microcrystalline cellulose, mannitol, or a spray-dried lactose system can improve blend uniformity and reduce segregation.
The development program should evaluate:
- API particle-size distribution.
- API surface area and electrostatic behavior.
- Ordered mixing or geometric dilution.
- Blend segregation during hopper transfer.
- Sampling adequacy for low-dose uniformity.
- Blend residence time and compression speed.
- Magnesium stearate concentration and mixing time.
A formulation that relies on a narrow API particle-size distribution can create supply risk. A more robust platform uses excipients that tolerate moderate API variability and preserve blend uniformity at commercial scale.
Disintegration and dissolution
Cyclobenzaprine is a weakly basic compound. Dissolution can vary with pH, particle size, wetting, and tablet hydrophobicity. A superdisintegrant combined with a wetting aid can support rapid release without requiring a large increase in tablet porosity.
The formulation should avoid excessive magnesium stearate or prolonged lubrication. Over-lubrication can reduce wettability, slow disintegration, and create dissolution variability. This risk is particularly relevant when the product is manufactured at high compression speed.
Lactose-free positioning
A lactose-free FEXMID tablet is a credible commercial opportunity. Many patients tolerate lactose-containing medicines without difficulty, but lactose avoidance is a simple differentiation point for pharmacy buyers, hospital formularies, and patients with lactose intolerance.
A lactose-free formulation could use:
- Microcrystalline cellulose and mannitol.
- Dibasic calcium phosphate, where dissolution and tablet size are acceptable.
- Copovidone or povidone as a binder.
- Croscarmellose sodium or crospovidone as a disintegrant.
Mannitol can improve mouthfeel and reduce the chalky sensation associated with some mineral fillers. It can also support orally disintegrating tablet development.
Color and identification
Cyclobenzaprine products are available in multiple strengths and manufacturers. A clearly differentiated tablet color, debossing pattern, or film-coat appearance can reduce dispensing errors between 5 mg, 7.5 mg, and 10 mg products.
The color system should meet current FDA expectations for inactive ingredients and avoid unnecessary use of dyes where a white or off-white tablet is commercially acceptable. A distinctive but simple imprint is generally more defensible than a complex color system.
What formulation patents could protect a FEXMID follow-on product?
The basic FEXMID immediate-release tablet is unlikely to support meaningful composition-of-matter protection because cyclobenzaprine is an established active ingredient. Commercial protection would more likely come from formulation, dosage-form, manufacturing, or method-of-use claims.
Potential claim categories include:
| Claim category |
Example commercial concept |
Relative opportunity |
| Orally disintegrating tablet |
Rapidly disintegrating cyclobenzaprine with improved mouthfeel |
High |
| Taste-masked tablet |
Reduced bitterness for patients with swallowing difficulty |
Moderate |
| Sprinkle formulation |
Capsule or granules suitable for administration with soft food |
Moderate |
| Lactose-free composition |
Excipients selected for lactose avoidance and rapid release |
Low to moderate |
| Modified-release product |
Once-daily cyclobenzaprine delivery |
High, but clinically and regulatorily complex |
| Abuse-deterrent formulation |
Reduced crushing, extraction, or rapid-release potential |
Limited to moderate |
| Pediatric formulation |
Lower-strength liquid, granule, or dispersible dosage form |
Limited by indication and safety |
| Manufacturing process |
Low-dose blending method with improved content uniformity |
Moderate |
Excipient selection alone usually provides weak patent protection if the ingredients are conventional and the claims are drafted broadly. Stronger protection requires a measurable technical effect, such as:
- A defined dissolution profile.
- Reduced food effect.
- Improved stability.
- Reduced impurity formation.
- Better content uniformity.
- A specified disintegration time.
- Improved palatability.
- Reduced sedation-related dosing errors through a differentiated release profile.
A formulation patent should connect excipient ranges to performance data. Claims limited to a list of known excipients face greater validity and freedom-to-operate risk.
When does FEXMID lose exclusivity?
Cyclobenzaprine immediate-release products have long been exposed to generic competition. The commercial issue is therefore not loss of core exclusivity but differentiation against multiple abbreviated new drug application products.
The original cyclobenzaprine franchise has no practical composition-of-matter barrier for a new entrant. Any remaining protection for a branded FEXMID presentation would depend on product-specific patents, listed patents, regulatory exclusivity, or commercial contracts.
Orange Book status
The FDA Orange Book should be checked for current FEXMID product listings and any patents submitted for the specific NDA. A branded immediate-release 7.5 mg product may have limited or no meaningful patent protection if its listed product characteristics are conventional.[2]
A market entrant should review:
- NDA and product number.
- Current marketing status.
- Listed patents and use codes.
- Patent delisting or expiration history.
- Therapeutic-equivalence codes for competing products.
- Whether the product is eligible for an ANDA referencing the same strength and dosage form.
A conventional immediate-release FEXMID tablet generally presents a lower regulatory barrier than an extended-release or novel-release product. A new dosage form that changes exposure, dosing frequency, or clinical use would likely require an NDA or 505(b)(2) pathway rather than a simple ANDA.
What generic entry risks exist for FEXMID?
Generic entry risk is high for the standard tablet. Cyclobenzaprine is an established molecule with broad generic availability, familiar manufacturing processes, and a large prior-art base.
The primary risks are:
- Price erosion from generic cyclobenzaprine 5 mg and 10 mg tablets.
- Therapeutic substitution by other muscle relaxants.
- Pharmacy benefit manager preference for low-cost generic products.
- Limited treatment duration, which constrains brand loyalty.
- Prescriber substitution between strengths.
- Low switching costs for pharmacies and wholesalers.
A differentiated product can reduce direct price comparison if it solves a clear problem. The strongest opportunities are formulations that improve administration rather than simply changing excipients.
Which FEXMID formulations have the strongest commercial potential?
Orally disintegrating tablet
An orally disintegrating tablet could target patients with dysphagia, acute pain, or limited access to water. The formulation would need effective taste masking because cyclobenzaprine can produce an unpleasant oral sensation.
Suitable excipient classes include mannitol, crospovidone, flavoring agents, sweeteners, and polymeric taste-masking systems. The product would require careful control of friability, packaging humidity, and in-mouth disintegration.
Once-daily modified-release product
Extended-release cyclobenzaprine already exists as a distinct product class. A new modified-release product could compete on tablet size, food-effect profile, dose flexibility, or abuse-deterrence characteristics.
This opportunity carries substantial development risk. The product would require pharmacokinetic bridging, dose selection, food-effect evaluation, and evidence that the release profile produces a meaningful clinical or adherence benefit.
Sprinkle or dispersible dosage form
A sprinkle product could support patients who cannot swallow tablets. It would need compatibility with soft foods, acceptable taste, dose uniformity after transfer, and stability after opening.
This product may be commercially narrower than an orally disintegrating tablet but could obtain stronger differentiation from conventional generics.
Lactose-free immediate-release tablet
This is the lowest-risk reformulation. It can use a standard excipient platform and may fit an ANDA or 505(b)(2) strategy depending on the product design and reference product. Its principal weakness is limited willingness to pay unless supported by pharmacy, institutional, or patient-channel demand.
How does FEXMID compare with competing muscle relaxants?
| Product class |
Typical differentiation |
FEXMID competitive position |
| Cyclobenzaprine 5 mg or 10 mg generic |
Lowest acquisition cost |
Weak on price |
| Cyclobenzaprine extended release |
Once-daily dosing |
FEXMID may compete on lower dose flexibility |
| Tizanidine |
Alternative mechanism and dosing profile |
Competes on prescriber familiarity but has hypotension and sedation concerns |
| Methocarbamol |
Generic, multiple strengths |
Strong pharmacy substitution risk |
| Baclofen |
Spasticity-focused use |
Less direct competition for acute musculoskeletal pain |
| Carisoprodol |
Rapid onset but controlled-substance concerns |
FEXMID can benefit from a less restrictive positioning |
Cyclobenzaprine’s commercial weakness is sedation and anticholinergic burden, especially in older adults. An excipient change cannot remove those pharmacologic liabilities. A product strategy should therefore focus on administration, adherence, dose precision, and pharmacy differentiation rather than claiming improved safety without clinical evidence.
What licensing and partnering opportunities exist?
Licensing opportunities are most credible in four areas:
- A proprietary orally disintegrating or taste-masked dosage form.
- A 505(b)(2) extended-release or lower-dose presentation.
- A contract manufacturing platform for low-dose, high-uniformity tablets.
- A regional brand or private-label product using a differentiated excipient system.
A conventional lactose-free tablet is more suitable for contract manufacturing, private labeling, or a regional generic strategy than for a high-value licensing deal. A product with validated clinical advantages, a protected release profile, or a strong patient-convenience benefit has greater partnering value.
Potential partners include generic manufacturers, specialty pharmaceutical companies, hospital suppliers, and firms with established orally disintegrating tablet technology. The most important diligence issues are freedom to operate, FDA therapeutic-equivalence strategy, manufacturing scale-up, and whether the formulation supports a premium over generic cyclobenzaprine.
What is the most attractive commercial strategy for FEXMID?
The best near-term strategy is a lactose-free, rapidly disintegrating 7.5 mg tablet with a differentiated imprint, compact packaging, and a formulation designed for low-dose content uniformity. This approach limits development risk and can target pharmacy, institutional, and specialty channels.
The higher-value strategy is a taste-masked orally disintegrating tablet or sprinkle formulation. It offers more defensible differentiation but requires greater work on palatability, stability, packaging, and product-specific intellectual property.
A once-daily formulation has the largest potential revenue expansion but also the highest regulatory and clinical risk. It should be treated as a separate development program rather than a simple excipient reformulation.
Key Takeaways
- FEXMID is a 7.5 mg immediate-release cyclobenzaprine hydrochloride tablet.
- The standard formulation uses conventional tablet excipients and has limited inherent differentiation.
- Generic entry risk is high because cyclobenzaprine is an established, broadly available molecule.
- A lactose-free tablet is commercially feasible but likely offers only modest pricing power.
- An orally disintegrating, taste-masked, or sprinkle formulation provides stronger commercial differentiation.
- Formulation patents should rely on measurable performance effects, not merely conventional excipient lists.
- Modified-release development offers greater revenue potential but requires a higher regulatory and clinical investment.
- The primary commercial barriers are generic pricing, short treatment duration, sedation, and anticholinergic tolerability.
- The best near-term opportunity is a patient-convenience formulation supported by robust low-dose content uniformity and rapid dissolution.
FAQs
Is FEXMID the same as cyclobenzaprine?
Yes. FEXMID is a branded product containing cyclobenzaprine hydrochloride at a 7.5 mg immediate-release tablet strength.
Can lactose-free FEXMID be developed with standard excipients?
Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, or another suitable filler, subject to dissolution, stability, manufacturability, and regulatory comparability requirements.
Would an orally disintegrating FEXMID require new clinical trials?
The requirement depends on the formulation, regulatory pathway, bioequivalence results, and labeling differences. A straightforward bioequivalent product may have a reduced clinical burden, while a product with modified exposure or new claims may require additional studies.
Does cyclobenzaprine have biosimilar risk?
No. Cyclobenzaprine is a small-molecule drug, not a biologic. The relevant competitive threat is generic substitution, not biosimilar entry.
Can excipients reduce FEXMID-related sedation?
No excipient can be assumed to remove cyclobenzaprine’s pharmacologic sedation or anticholinergic effects. A formulation may change absorption or exposure, but any safety claim requires supporting pharmacokinetic and clinical evidence.
References
- U.S. Food and Drug Administration. (n.d.). FEXMID (cyclobenzaprine hydrochloride) tablets, prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
